Tirzepatide
Metabolic
Tirzepatide is a synthetic 39-amino acid dual agonist peptide that simultaneously targets both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual receptor activity differentiates it mechanistically from single GLP-1 receptor agonists. It has been extensively studied in preclinical metabolic research models investigating glucose homeostasis, insulin secretion, and energy regulation pathways.
$85.00
In StockFor research purposes only. Not for human consumption.
Mechanism of Action
Tirzepatide acts as a dual agonist at GIP (GIPR) and GLP-1 (GLP-1R) receptors, triggering cAMP-mediated insulin secretion in a glucose-dependent manner. GIP receptor activation modulates adipocyte lipid metabolism and energy storage, while GLP-1 receptor activation inhibits glucagon secretion and delays gastric emptying. The combined dual agonism produces additive or synergistic effects on downstream metabolic signaling compared to single-receptor agonism.
Research Focus Areas
- Dual GIP/GLP-1 receptor signaling studies
- Glucose-dependent insulin secretion models
- Metabolic homeostasis pathway research
- Adipocyte lipid metabolism studies